DD229402A5 - Verfahren zur herstellung von piperidinion-derivaten, die als myocard-schutz eine antiarrhytmische aktivitaet ausweisen - Google Patents
Verfahren zur herstellung von piperidinion-derivaten, die als myocard-schutz eine antiarrhytmische aktivitaet ausweisen Download PDFInfo
- Publication number
- DD229402A5 DD229402A5 DD83270121A DD27012183A DD229402A5 DD 229402 A5 DD229402 A5 DD 229402A5 DD 83270121 A DD83270121 A DD 83270121A DD 27012183 A DD27012183 A DD 27012183A DD 229402 A5 DD229402 A5 DD 229402A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- alkyl group
- group
- carbon atoms
- hydrogen
- formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 13
- 230000000694 effects Effects 0.000 title description 5
- 238000004519 manufacturing process Methods 0.000 title description 2
- 239000003416 antiarrhythmic agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 8
- 239000001257 hydrogen Substances 0.000 claims abstract description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- CNMOHEDUVVUVPP-UHFFFAOYSA-N piperidine-2,3-dione Chemical group O=C1CCCNC1=O CNMOHEDUVVUVPP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 3
- 239000002904 solvent Substances 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 claims description 4
- 150000002825 nitriles Chemical class 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 230000029936 alkylation Effects 0.000 claims description 2
- 238000005804 alkylation reaction Methods 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000012442 inert solvent Substances 0.000 claims description 2
- 241000251730 Chondrichthyes Species 0.000 claims 1
- 239000003245 coal Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000003288 anthiarrhythmic effect Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 4
- 210000004165 myocardium Anatomy 0.000 abstract description 2
- 229940053994 hypnotics and sedatives piperidinedione derivative Drugs 0.000 abstract 1
- 230000005923 long-lasting effect Effects 0.000 abstract 1
- 150000005458 piperidinediones Chemical class 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 206010003119 arrhythmia Diseases 0.000 description 5
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GBFWRNRCKSYGEW-UHFFFAOYSA-N 1-hydroxypiperidin-2-ol Chemical class OC1CCCCN1O GBFWRNRCKSYGEW-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- QVDYYQXUNAQSNI-UHFFFAOYSA-N ethyl acetate;pentane Chemical compound CCCCC.CCOC(C)=O QVDYYQXUNAQSNI-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229910052500 inorganic mineral Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011707 mineral Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- LEWXPHFUQZGJBR-UHFFFAOYSA-N 3-[2-[di(propan-2-yl)amino]ethyl]-4,4,5,5-tetramethyl-3-pyridin-2-ylpiperidine-2,6-dione Chemical compound C=1C=CC=NC=1C1(CCN(C(C)C)C(C)C)C(=O)NC(=O)C(C)(C)C1(C)C LEWXPHFUQZGJBR-UHFFFAOYSA-N 0.000 description 1
- RNCVSWWWYHOYDS-UHFFFAOYSA-N 3-[2-[di(propan-2-yl)amino]ethyl]-4,5,5-trimethyl-3-pyridin-2-ylpiperidine-2,6-dione Chemical compound C=1C=CC=NC=1C1(CCN(C(C)C)C(C)C)C(C)C(C)(C)C(=O)NC1=O RNCVSWWWYHOYDS-UHFFFAOYSA-N 0.000 description 1
- AWSBGTCINOQWGE-UHFFFAOYSA-N 3-methyl-2-pyridin-2-ylbut-2-enenitrile Chemical compound CC(C)=C(C#N)C1=CC=CC=N1 AWSBGTCINOQWGE-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- -1 methyl-substituted morpholino Chemical group 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- DBVADBHSJCWFKI-UHFFFAOYSA-N n-(2-chloroethyl)-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)CCCl DBVADBHSJCWFKI-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical class O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8218706A FR2535721A1 (fr) | 1982-11-08 | 1982-11-08 | Derives de la piperidinedione protecteurs du myocarde presentant une acticite antiarythmique, leur procede de preparation et les medicaments qui contiennent lesdits derives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD229402A5 true DD229402A5 (de) | 1985-11-06 |
Family
ID=9279000
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD83270121A DD229402A5 (de) | 1982-11-08 | 1983-11-07 | Verfahren zur herstellung von piperidinion-derivaten, die als myocard-schutz eine antiarrhytmische aktivitaet ausweisen |
| DD83270120A DD229407A5 (de) | 1982-11-08 | 1983-11-07 | Verfahren zur herstellung von piperidindion-derivaten, die als myocard-schutz eine antiarrhytmische aktivitaet aufweisen |
| DD83256411A DD219770A5 (de) | 1982-11-08 | 1983-11-07 | Verfahren zur herstellung von piperidindion-derivaten |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD83270120A DD229407A5 (de) | 1982-11-08 | 1983-11-07 | Verfahren zur herstellung von piperidindion-derivaten, die als myocard-schutz eine antiarrhytmische aktivitaet aufweisen |
| DD83256411A DD219770A5 (de) | 1982-11-08 | 1983-11-07 | Verfahren zur herstellung von piperidindion-derivaten |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US4721710A (OSRAM) |
| EP (1) | EP0110755B1 (OSRAM) |
| JP (1) | JPS59161377A (OSRAM) |
| KR (1) | KR900006721B1 (OSRAM) |
| AT (1) | ATE22561T1 (OSRAM) |
| AU (1) | AU565519B2 (OSRAM) |
| CA (1) | CA1221967A (OSRAM) |
| CS (1) | CS244681B2 (OSRAM) |
| DD (3) | DD229402A5 (OSRAM) |
| DE (1) | DE3366623D1 (OSRAM) |
| DK (1) | DK511383A (OSRAM) |
| ES (1) | ES8406070A1 (OSRAM) |
| FI (1) | FI79536C (OSRAM) |
| FR (1) | FR2535721A1 (OSRAM) |
| GR (1) | GR78747B (OSRAM) |
| HU (1) | HU191494B (OSRAM) |
| IE (1) | IE56209B1 (OSRAM) |
| IL (1) | IL70099A (OSRAM) |
| MA (1) | MA19948A1 (OSRAM) |
| NO (1) | NO159852C (OSRAM) |
| NZ (1) | NZ206177A (OSRAM) |
| OA (1) | OA07582A (OSRAM) |
| PH (1) | PH20421A (OSRAM) |
| PL (3) | PL139946B1 (OSRAM) |
| PT (1) | PT77607B (OSRAM) |
| SG (1) | SG1989G (OSRAM) |
| SU (3) | SU1333237A3 (OSRAM) |
| YU (3) | YU221183A (OSRAM) |
| ZA (1) | ZA838065B (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4668689A (en) * | 1984-07-19 | 1987-05-26 | National Research Development Corporation | Glutarimide derivatives for treating oestrogen-dependent tumors |
| US5238947A (en) * | 1990-04-12 | 1993-08-24 | University Of Georgia Research Foundation, Inc. | Synthetic piperidinediones with cytostatic activity |
| US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| DE19703763C1 (de) * | 1997-02-01 | 1998-10-01 | Gruenenthal Gmbh | Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione |
| HUE033019T2 (en) | 2011-05-17 | 2017-11-28 | Principia Biopharma Inc | Tyrosine kinase inhibitors |
| HUE048834T2 (hu) | 2011-05-17 | 2020-08-28 | Univ California | Kináz inhibitorok |
| WO2012158795A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| SI2892900T1 (en) | 2012-09-10 | 2018-01-31 | Principia Biopharma Inc. | Pyrazolopyrimidine compounds as kinase inhibitors |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| MX372673B (es) | 2014-02-21 | 2020-03-25 | Principia Biopharma Inc | Un inhibidor de btk para usarse en el tratamiento de penfigo y sales y formas sólidas del mismo. |
| MA41197B1 (fr) | 2014-12-18 | 2021-01-29 | Principia Biopharma Inc | Traitement de le pemphigus |
| US20180305350A1 (en) | 2015-06-24 | 2018-10-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| EP3478273A1 (en) | 2016-06-29 | 2019-05-08 | Principia Biopharma Inc. | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| CN115209899A (zh) | 2019-10-14 | 2022-10-18 | 普林斯匹亚生物制药公司 | 通过施用(R)-2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁-3-基)哌嗪-1-基]戊-2-烯腈治疗免疫性血小板减少症的方法 |
| KR20220130184A (ko) | 2020-01-22 | 2022-09-26 | 프린시피아 바이오파마, 인코퍼레이티드 | 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)-1H-피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 결정질 형태 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2664424A (en) * | 1953-12-29 | Dioxo-piperidines | ||
| GB1455687A (en) * | 1972-12-28 | 1976-11-17 | Aspro Nicholas Ltd | Pharmacologically active 3-phenyl-3-aminoalkyl-2,6-dioxo-hydro genated pyridines |
| FR2467200A1 (fr) * | 1979-10-11 | 1981-04-17 | Clin Midy | Derives du pyrrole actifs sur les troubles du rythme cardiovasculaire |
-
1982
- 1982-11-08 FR FR8218706A patent/FR2535721A1/fr active Granted
-
1983
- 1983-10-28 ZA ZA838065A patent/ZA838065B/xx unknown
- 1983-10-31 IL IL70099A patent/IL70099A/xx unknown
- 1983-11-02 AU AU20898/83A patent/AU565519B2/en not_active Ceased
- 1983-11-04 EP EP83402142A patent/EP0110755B1/fr not_active Expired
- 1983-11-04 PT PT77607A patent/PT77607B/pt not_active IP Right Cessation
- 1983-11-04 IE IE2581/83A patent/IE56209B1/xx unknown
- 1983-11-04 AT AT83402142T patent/ATE22561T1/de not_active IP Right Cessation
- 1983-11-04 DE DE8383402142T patent/DE3366623D1/de not_active Expired
- 1983-11-04 GR GR72874A patent/GR78747B/el unknown
- 1983-11-05 SU SU833661804A patent/SU1333237A3/ru active
- 1983-11-07 MA MA20168A patent/MA19948A1/fr unknown
- 1983-11-07 NO NO834057A patent/NO159852C/no unknown
- 1983-11-07 DD DD83270121A patent/DD229402A5/de not_active IP Right Cessation
- 1983-11-07 DD DD83270120A patent/DD229407A5/de not_active IP Right Cessation
- 1983-11-07 DD DD83256411A patent/DD219770A5/de not_active IP Right Cessation
- 1983-11-07 NZ NZ206177A patent/NZ206177A/en unknown
- 1983-11-08 HU HU833827A patent/HU191494B/hu not_active IP Right Cessation
- 1983-11-08 PL PL1983244462A patent/PL139946B1/pl unknown
- 1983-11-08 KR KR1019830005288A patent/KR900006721B1/ko not_active Expired
- 1983-11-08 JP JP58209772A patent/JPS59161377A/ja active Pending
- 1983-11-08 ES ES527091A patent/ES8406070A1/es not_active Expired
- 1983-11-08 PL PL1983249749A patent/PL140992B1/pl unknown
- 1983-11-08 PH PH29800A patent/PH20421A/en unknown
- 1983-11-08 YU YU02211/83A patent/YU221183A/xx unknown
- 1983-11-08 CA CA000440675A patent/CA1221967A/en not_active Expired
- 1983-11-08 CS CS838220A patent/CS244681B2/cs unknown
- 1983-11-08 FI FI834087A patent/FI79536C/fi not_active IP Right Cessation
- 1983-11-08 DK DK511383A patent/DK511383A/da not_active Application Discontinuation
- 1983-11-08 PL PL1983249750A patent/PL140021B1/pl unknown
- 1983-11-08 OA OA58153A patent/OA07582A/xx unknown
-
1984
- 1984-09-06 SU SU843786907A patent/SU1316558A3/ru active
- 1984-09-06 SU SU843786916A patent/SU1333238A3/ru active
-
1985
- 1985-11-26 YU YU01841/85A patent/YU184185A/xx unknown
- 1985-11-26 YU YU01842/85A patent/YU184285A/xx unknown
-
1986
- 1986-03-10 US US06/838,255 patent/US4721710A/en not_active Expired - Fee Related
-
1989
- 1989-01-11 SG SG19/89A patent/SG1989G/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1695556C3 (de) | 3-Alkyl-1,2,3,4,4a,9-hexahydropyrazino[1,2-f]morphanthridinderivate | |
| DD229402A5 (de) | Verfahren zur herstellung von piperidinion-derivaten, die als myocard-schutz eine antiarrhytmische aktivitaet ausweisen | |
| DE2558501C2 (OSRAM) | ||
| DD146600A5 (de) | Verfahren zur herstellung von n hoch 2-arylsulfonyl-l-argininamiden und der pharmazeutisch annehmbaren salze | |
| DD227963A5 (de) | Verfahren zur herstellung von 1-benzyl-aminoalkyl-pyrrolidinone | |
| DE2845499A1 (de) | Alkanoylprolin-derivate und deren homologen, ihre herstellung und verwendung | |
| DE69627344T2 (de) | N-(2,4-dioxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3-yl)-3-amide | |
| DE3232462A1 (de) | 2-nitro-1,1-ethendiamine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel | |
| DE69002338T2 (de) | Pyrrolidin-Derivate und ihre pharmazeutische Verwendung. | |
| DE3216843C2 (de) | 3-Thiomethyl-pyridin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE2802864A1 (de) | 3-isobutoxy-2-pyrrolidino-n-phenyl- n-benzylpropylamin, verfahren zu seiner herstellung und es enthaltende arzneimittel | |
| CH618439A5 (OSRAM) | ||
| DE68912252T2 (de) | Imidazolantiarrythmische Mittel. | |
| DE2007345A1 (de) | Neue substituierte Hexahydroimidazochinoline und deren Säureanlagerungssalze | |
| DE3723648A1 (de) | Indol-derivate, ihre herstellung und sie enthaltende arzneimittel | |
| DD205682A5 (de) | Verfahren zur herstellung von (-)-2-(1-(2,6-dichlorphenoxy)-ethyl)-1,3-diazacyclopent-2-en und seinen salzen | |
| DE2359816C2 (OSRAM) | ||
| DD153549A5 (de) | Verfahren zur herstellung von pyridinderivaten | |
| DE3813416A1 (de) | 3,4-dihydroxypyrrolidin-2-on-derivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung sowie die bei der herstellung anfallenden neuen zwischenprodukte | |
| DE2023829C3 (de) | Kernsubstituierte 3-Phenoxy-lphenoxyalkyl-amino-propan-2-oIe, Verfahren zu ihrer Herstellung sowie Arzneimittel | |
| DD231567A5 (de) | Verfahren zur herstellung von gamma-butyrolacton-derivaten, die als myocard-schutz eine antiarrhythmische wirkung aufweisen | |
| DE69632206T2 (de) | (2-piperidin-1-yl-4-substituierte)-4-amino-2-chinazolin-derivate mit antihypertensiver wirkung, verfahren zu ihrer herstellung und ihrem pharmazeutischen gebrauch | |
| EP0269985A2 (de) | Neue 1-Aryloxy-3-amino-2-propanole, ihre Herstellung und Verwendung | |
| EP0266336A1 (de) | Neue 1-/ 3-(2-Dialkylaminoäthoxy)-2-thienyl/-3-phenyl-1-propanone und ihre Säureadditionssalze und Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen | |
| CH615181A5 (en) | Process for the preparation of novel ergolene derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |